Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Drug Diversion Concerns on the Rise

Kurt Ullman  |  Issue: September 2012  |  September 5, 2012

There is also an important patient-teaching piece. He will often suggest that patients put their pain medications in a locked cabinet to cut down on the possibility of theft. Another tip is to make sure those medications are kept out of visual range of visitors.

Evaluating Sources

For the physician, there are certain things to look for when evaluating sources for medication supply. First is whether or not the potential vendor is licensed by the appropriate federal and state authorities. If there are doubts, contact the maker of the medication to confirm that you are dealing with an established source of the company’s product.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Other indicators include:

  • Packaging materials in a nonexpected language;
  • Spelling or grammatical errors on the insert or the outside packaging;
  • Package in poor condition;
  • Seals that are not intact; and
  • A look, color, and consistency of the product that is inconsistent with what you have seen previously.

“Price should be another red flag,” notes Kent. “There is a reason that these drugs are being sold so cheaply. They are not having to pay the costs associated with a regulated supply chain that produces a secure product.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

For the physician-administered medications, there are liability concerns that accrue when buying medications outside normal channels.

“It is a very high-risk activity,” says Dr. Mollo. “It brings exposure to malpractice if the medication is adulterated or the wrong strength. There is also the potential for criminal liability when submitting payment claims if products are not approved for use in the U.S.”

Medication Samples

Diverting medication samples sits at the cusp of legal and illegal uses. On the one hand, samples obtained from the pharmaceutical company or their proxies most often flows through legitimate markets. On the other, selling medications obtained for free constitutes fraud when paid for by Medicare, Medicaid, or insurance companies.

The rise of mail-order and Internet-based sources for medications has further muddied the waters, especially when patients are involved. Although many of these advertise cheap medicines, it is very much a buyer-beware endeavor.

“The FDA advises consumers to use caution when buying prescription medicines online as many websites that appear to reputable and similar to legitimate retail pharmacies actually operate from outside the United States,” says Clark-Lynn. “It is very easy for these online resellers to pretend to be from Canada or another country when they are really operating from the far reaches of the globe. Although a country may have a strong regulatory process, U.S. consumers cannot rely on the fact that the products they are buying have been approved in that country.”

Internet and Mail-Order Sources

The experts agree that the Internet sites of established national, regional, and local pharmacies are as safe as their brick-and-mortar affiliates. A person can also confidently use mail-order outlets of these companies and any mail-order pharmacies endorsed by their insurance companies.

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:Drug UpdatesLegislation & AdvocacyProfessional Topics Tagged with:drugLegislationMedicareMedicationpharmaceuticalrheumatologistSafety

Related Articles

    2014 ACR/ARHP Annual Meeting: Rheumatology Drug Updates, Safety News

    January 1, 2015

    Plus, hydrocodone combination products and brodalumab

    U.S. Lets More Healthcare Workers Prescribe Opioid Addiction Treatment

    January 24, 2018

    WASHINGTON (Reuters)—The U.S. Drug Enforcement Administration said on Tuesday it had changed a regulation to allow more healthcare professionals to prescribe a medication used to treat opioid addiction, opening up access in rural America where there are few doctors.1 Prior to 2000, only physicians could treat those with opioid addiction and had to register with…

    DEA Proposes Cutting Production of Come Opioids

    August 7, 2017

    (Reuters)—The U.S. Drug Enforcement Administration (DEA) on Friday proposed a 20% reduction in the manufacture of certain commonly prescribed opioid painkillers, as well as other controlled substances for next year. The proposal comes as U.S. regulators and lawmakers take steps to limit the supply of opioids—a class of drugs that include prescription painkillers and heroin—to…

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    April 15, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences